Neoplasm Metastasis
|
0.400 |
AlteredExpression
|
phenotype |
BEFREE |
PTEN expression was significantly associated with invasive depth (P=0.003, rs=0.274), metastasis (P=0.036, rs=0.197), growth pattern (P=0.008, rs=0.282), Lauren's classification (P=0.000, rs=0.345), and histological classification (P=0.005, rs=0.262) of tumors, but not with tumor size (P=0.639, rs=0.045), Borrmann's classification (P=0.544, rs=0.070) or TNM staging (P=0.172, rs=0.129).
|
12918097 |
2003 |
Neoplasm Metastasis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
PTEN status on primary tumors and pAKT status both on primary tumors and on metastases did not predict response or progression-free survival (PFS).
|
19398573 |
2009 |
Neoplasm Metastasis
|
0.400 |
PosttranslationalModification
|
phenotype |
BEFREE |
PTEN methylation was significantly associated with early metastasis.
|
23139750 |
2012 |
Neoplasm Metastasis
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
PTEN mutations were associated with nodal metastases.
|
23728071 |
2013 |
Neoplasm Metastasis
|
0.400 |
AlteredExpression
|
phenotype |
BEFREE |
PTEN expression in CAFs in distant metastases was lost in 11 of 181 CRC patients (6.1%), which was associated with a worse prognosis.
|
24642707 |
2014 |
Neoplasm Metastasis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
PTEN loss in metastases appears to be associated with response to bevacizumab-based therapy.
|
24980447 |
2015 |
Neoplasm Metastasis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
Phosphatase and tensin homolog deleted on chromosome 10 (PTEN) insufficiency is commonly found in breast cancer patients with metastasis.
|
27466505 |
2016 |
Neoplasm Metastasis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
PTEN, a critical tumor and metastasis suppressor gene negatively regulates cell survival, proliferation, migration and angiogenesis via the PI3K/Akt pathway.
|
27634912 |
2016 |
Neoplasm Metastasis
|
0.400 |
AlteredExpression
|
phenotype |
BEFREE |
PTEN expression was significantly correlated with gender, smoking history, histology (adenocarcinoma [ADC] vs. squamous cell carcinoma), tumor node metastasis stage (I-II vs. III-IV), N status (N0 vs. N1-N3), and distant metastasis (M0 vs. M1).
|
28263037 |
2017 |
Neoplasm Metastasis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
Phosphatase and tensin homolog protein may be linked to lymph node metastasis and tumor node metastasis staging in nonsmall cell lung cancer.
|
29578164 |
2018 |
Neoplasm Metastasis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
Phosphatase and tensin homolog (PTEN) deficiency is associated with development, progression, and metastasis of various cancers.
|
30226608 |
2018 |
Neoplasm Metastasis
|
0.400 |
AlteredExpression
|
phenotype |
BEFREE |
Activating mutations in the PIK3CA gene or loss of PTEN expression did not correlate with distant metastasis while high nuclear β-Catenin expression combined with activation of the PI3K pathway identified cases in which distant metastasis had occurred.
|
24930890 |
2014 |
Neoplasm Metastasis
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
Alteration of the PTEN/MMAC1 gene locus in primary lung cancer with distant metastasis.
|
10470842 |
1999 |
Neoplasm Metastasis
|
0.400 |
AlteredExpression
|
phenotype |
BEFREE |
Among patients without distant metastases (n = 282), a high pretreatment PTEN mRNA level was associated with inferior relapse-free (RFS; p = 0.001) and disease-specific survival (DSS; p = 0.003).
|
28213783 |
2017 |
Neoplasm Metastasis
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
Array-based comparative genomic hybridization revealed genetic alterations common to both SU-1 and SU-2, including amplification of the oncogene EGFR and deletion of the tumor suppressor PTEN, while some genetic alterations such as amplification of MTA1 (metastasis associated gene 1) only occurred in SU-2.
|
18940013 |
2008 |
Neoplasm Metastasis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
Because PTEN negatively regulates on the downstream effects of phosphatidylinositol-3-kinase (PI3-K), we hypothesized that the loss of PTEN/MMAC1 and the activation of RAS may be largely equivalent because RAS is a known positive upstream regulator of PI3-K. We expanded our previous survey of PTEN/MMAC1 mutations and analyzed the RAS status of 53 cutaneous melanoma cell lines, 18 glioma cell lines, and 17 uncultured cutaneous melanoma metastasis.
|
10766161 |
2000 |
Neoplasm Metastasis
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
Biallelic deletion of PTEN has been associated with advanced stage tumors or metastatic disease.
|
15448614 |
2004 |
Neoplasm Metastasis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
Bioinformatics analysis combined with tumor metastasis PCR array showed that matrix metalloproteinase 2 (MMP2) and PTEN could be important target genes of miR-29b.
|
26063204 |
2015 |
Neoplasm Metastasis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
CCAT2 was an endogenous sponge by competing for miR-216b, and miR-216b suppression alleviated CCAT2 silence-diminished cell growth and metastasis. miR-216b negatively regulated Bcl-2 and Bcl-2 could further active PTEN/PI3K/AKT and mTOR signaling pathways.
|
29036788 |
2017 |
Neoplasm Metastasis
|
0.400 |
AlteredExpression
|
phenotype |
BEFREE |
Chemerin upregulated expression and phosphatase activity of PTEN by interfering with PTEN-CMKLR1 interaction, leading to weakened ubiquitination of PTEN and decreased p-Akt (Ser473) level, which was responsible for suppressed migration, invasion and metastasis of HCC cells.
|
29717200 |
2018 |
Neoplasm Metastasis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
Collectively, our data identified a tumor inducer, SYNJ2BP, which could activate the PI3K/AKT/GSK3β/SNAI1 signaling pathway through the lysosome-mediated degradation of PTEN, and promote both EMT and tumor metastasis during the progression of breast cancer.
|
29163781 |
2017 |
Neoplasm Metastasis
|
0.400 |
AlteredExpression
|
phenotype |
BEFREE |
Compared with the supraglottic carcinoma with no lymph node metastasis, the expression of metastasis inhibitor genes PTEN and thrombospondin 2 was down-regulated in the supraglottic carcinoma tissue with lymph node metastasis.
|
18720079 |
2009 |
Neoplasm Metastasis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
Concomitant PTEN protein loss in tumour and juxta-tumoural stroma, found in 21.4% of PDACs, correlated with increased distant metastasis (p = 0.0045).
|
27475963 |
2016 |
Neoplasm Metastasis
|
0.400 |
AlteredExpression
|
phenotype |
BEFREE |
Concordant analysis of KRAS, BRAF, PIK3CA mutations, and PTEN expression between primary colorectal cancer and matched metastases.
|
25639985 |
2015 |
Neoplasm Metastasis
|
0.400 |
AlteredExpression
|
phenotype |
BEFREE |
Conversely, PTEN protein expression was markedly lower in CRC compared with adjacent normal tissues. p‑4E‑BP1 protein upregulation tissues samples was consistent with PTEN downregulation in CRC samples. p‑4E‑BP1 overexpression was predominant in patients with metastasis to the regional lymph nodes.
|
28339030 |
2017 |